Efficacy of preventive use of oxygen therapy after planned extubation in high-risk patients with extubation failure: A network meta-analysis of randomized controlled trials. 2022

Xiaozhuo Zheng, and Rui Wang, and Mohan Giri, and Jun Duan, and Mengyi Ma, and Shuliang Guo
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Extubation failure is common in critically ill patients, especially those with high-risk factors, and is associated with poor prognosis. Prophylactic use of oxygen therapy after extubation has been gradually introduced. However, the best respiratory support method is still unclear. This study aimed to evaluate the efficacy of four post-extubation respiratory support approaches in reducing reintubation and respiratory failure in patients at high-risk of extubation failure. A comprehensive search was performed in Cochrane Central Register of Controlled Trials, PubMed, EMBASE, and Web of Science from inception to June 2022. Randomized controlled trials (RCTs) comparing post-extubation preventive use of respiratory management strategies, including conventional oxygen therapy (COT), non-invasive ventilation (NIV), and high-flow nasal catheter (HFNC) in high-risk patients with extubation failure were reviewed. Primary outcomes were reintubation rate and respiratory failure. Secondary outcomes included intensive care unit (ICU) mortality, ICU stay and length of hospital stay (LOS). Seventeen RCTs comprising 2813 participants were enrolled. Compared with COT, the three respiratory support methods (NIV, HFNC, NIV + HFNC) were all effective in preventing reintubation [odds ratio (OR) 0.46, 95% confidence interval (CI) 0.32-0.67; OR 0.26, 95% CI 0.14-0.48; OR 0.62, 95% CI 0.39-0.97, respectively] and respiratory failure (OR 0.23, 95% CI 0.10-0.52; OR 0.15, 95% CI 0.04-0.60; OR 0.26, 95% CI 0.10-0.72, respectively). NIV and NIV + HFNC also reduced ICU mortality (OR 0.40, 95% CI 0.22-0.74; OR 0.32, 95% CI 0.12-0.85). NIV + HFNC ranked best in terms of reintubation rate, respiratory failure and ICU mortality based on the surface under the cumulative ranking curve (SUCRA) (99.3, 87.1, 88.2, respectively). Although there was no significant difference in shortening ICU stay and LOS among the four methods, HFNC ranked first based on the SUCRA. Preventive use of NIV + HFNC after scheduled extubation is probably the most effective respiratory support method for preventing reintubation, respiratory failure and ICU death in high-risk patients with extubation failure. HFNC alone seems to be the best method to shorten ICU stay and LOS. [https://www.crd.york.ac.uk/prospero/], identifier [CRD42022340623].

UI MeSH Term Description Entries

Related Publications

Xiaozhuo Zheng, and Rui Wang, and Mohan Giri, and Jun Duan, and Mengyi Ma, and Shuliang Guo
September 2019, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine,
Xiaozhuo Zheng, and Rui Wang, and Mohan Giri, and Jun Duan, and Mengyi Ma, and Shuliang Guo
June 2020, Critical care (London, England),
Xiaozhuo Zheng, and Rui Wang, and Mohan Giri, and Jun Duan, and Mengyi Ma, and Shuliang Guo
January 2015, Heart & lung : the journal of critical care,
Xiaozhuo Zheng, and Rui Wang, and Mohan Giri, and Jun Duan, and Mengyi Ma, and Shuliang Guo
May 2019, Critical care (London, England),
Xiaozhuo Zheng, and Rui Wang, and Mohan Giri, and Jun Duan, and Mengyi Ma, and Shuliang Guo
January 2022, International journal of chronic obstructive pulmonary disease,
Xiaozhuo Zheng, and Rui Wang, and Mohan Giri, and Jun Duan, and Mengyi Ma, and Shuliang Guo
November 2019, Critical care (London, England),
Xiaozhuo Zheng, and Rui Wang, and Mohan Giri, and Jun Duan, and Mengyi Ma, and Shuliang Guo
December 2017, BMC pulmonary medicine,
Xiaozhuo Zheng, and Rui Wang, and Mohan Giri, and Jun Duan, and Mengyi Ma, and Shuliang Guo
February 2012, Respiratory care,
Xiaozhuo Zheng, and Rui Wang, and Mohan Giri, and Jun Duan, and Mengyi Ma, and Shuliang Guo
May 2022, Clinical therapeutics,
Copied contents to your clipboard!